At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
MOR202drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)
In Brief
A Phase 2 clinical trial evaluating MOR202 for Glomerulonephritis, Membranous and antiPLA2R Positive. Completed, enrolled 31 participants across 45 sites in 9 countries.
Detailed Summary
This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlomerulonephritis, Membranous, antiPLA2R Positive
CountriesAustralia, Belgium, France, Italy, Netherlands, Poland, South Korea, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedOct 2019
Primary CompletionJan 2022
Study CompletionAug 2022
TodayJul 2026
First PostedOct 30, 2019
Enrollment StartOct 15, 2019
Primary CompletionJan 19, 2022
Study CompletionAug 2, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.7 years ago
Interventions
MOR202drug
Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.